Genetesis, Inc

Based in the US, Genetesis, Inc operates as a pioneer in advanced cardiac imaging, utilizing innovative technology to enhance healthcare outcomes. Genetesis, Inc specializes in advanced cardiac imaging solutions centered around its flagship product, CardioFlux. Founded in 2013 in Mason, US, the company has successfully conducted seven investment deals with its latest funding round occurring on October 6, 2022. In this Series C round, Genetesis raised USD 17.

5 mn, led by Mithril Capital Management, with participation from Cercano Management, CincyTech, JobsOhio, and the Ohio Innovation Fund. The company was co-founded by Manny Setegn and Peeyush Shrivastava, who serves as the CEO. Genetesis specializes in advanced cardiac imaging solutions, primarily through its flagship product, CardioFlux. This innovative device utilizes magnetocardiography (MCG) technology to non-invasively measure and visualize the magnetic signals generated by the electrical currents in the heart.

CardioFlux enables the rapid detection of functionally significant ischemia within a five-minute scanning window, significantly reducing the time and complexity associated with traditional cardiac assessments such as stress testing and observation periods. The device is designed to streamline workflows in clinical settings, thus improving patient care by allowing healthcare providers to make quicker and more informed decisions about treatment. The primary end users of CardioFlux include healthcare institutions, cardiology departments, and emergency medicine practitioners, with technology currently approved for use in Canada and possessing FDA 510(k) clearance in the US market. Genetesis generates revenue through the sale and deployment of its CardioFlux MCG technology within healthcare facilities.

The company typically engages in B2B transactions, partnering with hospitals and diagnostic centers to integrate CardioFlux into their existing cardiac imaging workflows. This partnership model allows healthcare providers to obtain the technology either through direct purchase or leasing agreements, facilitating access to advanced diagnostic capabilities without significant upfront capital expenses. Strategic collaborations with other healthcare providers enhance the firm's market presence and assist in establishing standard care protocols. While specific pricing details are not disclosed, revenue is driven by the utilization of CardioFlux in clinical assessments, with an emphasis on improving patient outcomes and expediting diagnosis in cases of suspected myocardial ischemia.

In October 2022, Genetesis, Inc raised USD 17. 5 mn in Series C funding, which will be utilized to accelerate FDA approval and implement pilot programs for the Merlin Automated Lab, aimed at delivering on-site, real-time blood test results. The company plans to expand its market reach, focusing on new geographic regions to enhance its presence in the healthcare industry. Specific target markets for expansion have not been detailed, but the funding will support ongoing development and market introduction of innovative products.